What is 21 CFR Part 111?

21 CFR Part 111 is the FDA regulation that establishes Current Good Manufacturing Practice (cGMP) requirements for dietary supplements. It covers eight areas: personnel, physical plant and grounds, equipment and utensils, production and process controls, holding and distribution, returned products, product complaints, and recordkeeping. It applies operation by operation to facilities that manufacture, package, label, or hold dietary supplements, with a narrow exemption in 21 CFR 111.1(b) for retail establishments holding product solely for direct sale to individual consumers. The regulation has been in effect since 2010 for all facility sizes.

Does Part 111 apply to my brand if I use a contract manufacturer?

Yes. While your contract manufacturer bears direct responsibility for cGMP compliance in their facility, you as the brand owner share regulatory responsibility for the products sold under your label. The FDA can and does hold brand owners accountable when products are adulterated or misbranded. This is why verifying your manufacturer's compliance through facility audits, documentation review, and third-party certifications is a core part of brand-side quality management.

What are the most common FDA cGMP violations for supplement facilities?

Based on published analyses of FDA 483 observations and warning letters (for example, cGMP Consulting's review of FY2024 483 data, which found component identity-testing citations rose sharply), the most frequently cited violation categories include: failure to establish product specifications for identity, purity, strength, and composition; failure to conduct at least one appropriate identity test on each incoming dietary ingredient (21 CFR 111.75(a)(1); FDA can grant an exemption only through the petition process at 111.75(a)(1)(ii), and other components may rely on an ingredient supplier's certificate of analysis with periodic confirmation under 111.75(a)(2)); failure to establish and follow written master manufacturing records; inadequate testing of finished products; and failure to hold reserve samples.

21 CFR Part 111: What Brands Need to Know

Last reviewed: March 13, 2026 | Next review: September 11, 2026

By Greg Huang, founder since 2009 in the dietary supplement and nutrition industry

Reviewed by Dr. James Pendleton, ND, licensed primary care physician, 20+ years in naturopathic medicine

The short answer

21 CFR Part 111 is the FDA's current good manufacturing practice (cGMP) regulation for dietary supplements, finalized in 2007. It applies, operation by operation, to facilities that manufacture, package, label, or hold supplements sold in the United States (with a narrow exemption for retail establishments holding product solely for direct sale to individual consumers), across sixteen subparts. Core requirements include ingredient identity testing (§111.75) and designated quality control personnel (§111.105). FDA holds brands and manufacturers both accountable.

If you sell dietary supplements in the United States, the manufacturers you work with must comply with 21 CFR Part 111. This guide explains what Part 111 requires in plain language, without regulatory jargon or legalese. If you are new to manufacturing regulations entirely, start with our primer on what GMPs are and come back here for the Part 111 specifics.

Dietary supplement manufacturers must comply with 21 CFR Part 111 (Current Good Manufacturing Practice for dietary supplements). This includes requirements for personnel, facilities, equipment, production, laboratory operations, and record-keeping.

What Part 111 Is

21 CFR Part 111 is the FDA regulation that establishes Current Good Manufacturing Practice (cGMP)for dietary supplements. It was finalized in 2007 and applies, operation by operation, to companies that manufacture, package, label, or hold dietary supplements sold in the United States. The one narrow carve-out: under 21 CFR 111.1(b), the holding requirements do not apply to a retail establishment holding product solely for direct sale to individual consumers (a retailer's warehouse does not qualify for that exemption).

The regulation covers the entire manufacturing process, from receiving raw materials to shipping finished products. Its purpose is to ensure that dietary supplements are produced consistently, meet quality standards, and contain what their labels say they contain.

Who It Applies To

Part 111 applies, operation by operation, to domestic and foreign facilities that manufacture, package, label, or hold dietary supplements for sale in the U.S. (retail establishments holding product solely for direct sale to individual consumers are exempt from the holding requirements under 21 CFR 111.1(b)). Facilities it covers include:

Contract manufacturers (CMs) who produce supplements for brands
Co-packers who package or label products
Warehouses and distribution centers that hold dietary supplements
Brands that manufacture their own products in-house

As a brand, Part 111 obligations attach to the operations you actually perform: if your own business packages, relabels, warehouses, or distributes product (not just manufactures), the subparts covering those operations apply to you directly. A brand that outsources everything still carries responsibility for choosing compliant manufacturers, and FDA holds own-label distributors accountable for their supply chain. If your CM isn't cGMP-compliant, your products are non-compliant.

What Part 111 Covers

Part 111 is organized into sixteen subparts, labeled A through P. In plain language, they group into these core operational areas.

Personnel

People who work in supplement manufacturing must be qualified for their jobs and trained in cGMP, hygiene, and their specific responsibilities. The regulation requires a designated quality control person with education, training, or experience to make quality decisions.

Physical Plant and Grounds

Manufacturing facilities must be designed and maintained to prevent contamination. This covers building design, water systems, plumbing, sewage, pest control, cleaning, and sanitation. Separate areas are required for different operations to prevent cross-contamination.

Equipment and Utensils

All equipment used in manufacturing must be appropriate for its intended use, maintained in a clean and sanitary condition, and calibrated regularly. Automatic, mechanical, and electronic equipment must be routinely inspected and validated.

Production and Process Control System

Manufacturers must have a written production and process control system. This includes master manufacturing records (the recipe), batch production records (what actually happened), and procedures for every step from receiving materials to releasing finished product.

Production and In-Process Controls

This is the detailed "how" of manufacturing. It covers receiving and inspecting raw materials, identifying and holding components, producing supplements according to the master record, sampling and testing during production, handling reprocessing, and managing rejected materials.

Laboratory Operations

Testing requirements for raw materials and finished products. Labs must use scientifically valid methods, maintain proper records, and test for identity, purity, strength, and composition. Manufacturers can use in-house labs, contract labs, or both.

Holding and Distribution

Requirements for storing components and finished products under appropriate conditions (temperature, humidity, light). Distribution records must be maintained to enable product recalls when necessary.

Records and Recordkeeping

Detailed requirements for what records must be kept and for how long (21 CFR 111.605): one year past the shelf-life date when the product carries one, otherwise two years beyond the date of distribution of the last batch associated with those records. This includes batch records, lab results, complaint files, and returned product records.

Common FDA Violations

FDA publishes warning letters and inspection observations (Form 483s) publicly. Based on these records, the most common Part 111 violations include:

Failure to establish product specifications. Not defining what the finished product should contain, including identity, purity, strength, and composition limits.
Failure to test components for identity before use. Using raw materials without confirming they are what the supplier says they are.
Failure to establish and follow written production procedures. No master manufacturing records, or manufacturing that deviates from written procedures without documentation.
Inadequate testing of finished products. Releasing products without testing for identity, purity, strength, composition, and contamination.
Inadequate batch production records. Incomplete documentation of what happened during production: missing times, temperatures, quantities, or personnel records.
Failure to investigate complaints and adverse events. Not maintaining a system to receive, evaluate, and respond to product complaints.

Source: FDA warning letters and 483 observations are publicly available on the FDA website.

What This Means for Brands

If you're a brand working with contract manufacturers, Part 111 compliance should be a baseline requirement, not a bonus. Here's what you should do:

Confirm your CM is FDA registered and can provide their registration number
Ask for their most recent third-party cGMP audit report
Request documentation of their production and process control system
Verify they test raw materials for identity and finished products for specifications
Review their complaint handling and adverse event reporting procedures
Include cGMP compliance requirements in your manufacturing agreement

For a complete framework on evaluating manufacturers, see our guide to evaluating supplement manufacturers.

Greg Huang, founder since 2009 in the dietary supplement and nutrition industry

Founder of Inventory Ready. Previously founded and operated multiple consumer brands in the dietary supplement and nutrition industry since summer 2009.

Concepts Covered

21 CFR Part 111 cGMP (Current Good Manufacturing Practice)Identity Testing Potency Testing Batch Record FDA Inspection FDA Warning Letter

Stay informed

Regulatory updates, new manufacturer assessments, and tool launches. No spam.

Disclaimer: This guide is educational content based on publicly available FDA regulations and enforcement records. It is not legal or regulatory advice. The full text of 21 CFR Part 111 is available on the Electronic Code of Federal Regulations. Consult qualified regulatory counsel for compliance guidance. See our Terms of Service.

Primary sources

The sourced claims in this guide are grounded in the following primary references. The guide's source manifest maps each claim to its source and verification date.